BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37295388)

  • 1. Identification of signature genes and drug candidates for primary plasma cell leukemia: An integrated system biology approach.
    Chaudhary RK; Patil P; Ananthesh L; Gowdru Srinivasa M; Mateti UV; Shetty V; Khanal P
    Comput Biol Med; 2023 Aug; 162():107090. PubMed ID: 37295388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated Bioinformatics Analysis for the Screening of Hub Genes and Therapeutic Drugs in Hepatocellular Carcinoma.
    Su Q; Li W; Zhang X; Wu R; Zheng K; Zhou T; Dong Y; He Y; Wang D; Ran J
    Curr Pharm Biotechnol; 2023; 24(8):1035-1058. PubMed ID: 35762549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico analysis to identify miR-1271-5p/PLCB4 (phospholipase C Beta 4) axis mediated oxaliplatin resistance in metastatic colorectal cancer.
    Lee CC; Lee AW; Wei PL; Liu YS; Chang YJ; Huang CY
    Sci Rep; 2023 Mar; 13(1):4366. PubMed ID: 36927770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
    Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
    J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysis.
    Chen B; Sun D; Qin X; Gao XH
    Invest New Drugs; 2021 Aug; 39(4):928-948. PubMed ID: 33501609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of hub genes with prognostic values in gastric cancer by bioinformatics analysis.
    Li T; Gao X; Han L; Yu J; Li H
    World J Surg Oncol; 2018 Jun; 16(1):114. PubMed ID: 29921304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioinformatics Analysis of Candidate Genes and Pathways Related to Hepatocellular Carcinoma in China: A Study Based on Public Databases.
    Zhang P; Feng J; Wu X; Chu W; Zhang Y; Li P
    Pathol Oncol Res; 2021; 27():588532. PubMed ID: 34257537
    [No Abstract]   [Full Text] [Related]  

  • 8. Screening and identification of hub genes in pancreatic cancer by integrated bioinformatics analysis.
    Chen Q; Yu D; Zhao Y; Qiu J; Xie Y; Tao M
    J Cell Biochem; 2019 Dec; 120(12):19496-19508. PubMed ID: 31297881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common gene signatures and key pathways in hypopharyngeal and esophageal squamous cell carcinoma: Evidence from bioinformatic analysis.
    Zhou R; Liu D; Zhu J; Zhang T
    Medicine (Baltimore); 2020 Oct; 99(42):e22434. PubMed ID: 33080677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated Bioinformatics Analysis of mRNAs and miRNAs Identified Potential Biomarkers of Oral Squamous Cell Carcinoma.
    Amiri-Dashatan N; Koushki M; Jalilian A; Ahmadi NA; Rezaei-Tavirani M
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1841-1848. PubMed ID: 32597160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of significant genes associated with prognosis of gastric cancer by bioinformatics analysis.
    Wang S; Tao S; Liu Y; Shi Y; Liu M
    J Egypt Natl Canc Inst; 2022 Dec; 34(1):55. PubMed ID: 36567425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of differentially expressed genes regulated by molecular signature in breast cancer-associated fibroblasts by bioinformatics analysis.
    Vastrad B; Vastrad C; Tengli A; Iliger S
    Arch Gynecol Obstet; 2018 Jan; 297(1):161-183. PubMed ID: 29063236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldehyde Dehydrogenase 2 Family Member (ALDH2) Is a Therapeutic Index for Oxaliplatin Response on Colorectal Cancer Therapy with Dysfunction p53.
    Wang WL; Batzorig U; Hung CS; Wei PL; Huang CY; Chang YJ
    Biomed Res Int; 2022; 2022():1322788. PubMed ID: 35178443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Potential Hub Genes and Therapeutic Drugs in Malignant Pleural Mesothelioma by Integrated Bioinformatics Analysis.
    Zhang X; Yang L; Chen W; Kong M
    Oncol Res Treat; 2020; 43(12):656-671. PubMed ID: 33032291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening Hub Genes as Prognostic Biomarkers of Hepatocellular Carcinoma by Bioinformatics Analysis.
    Zhou Z; Li Y; Hao H; Wang Y; Zhou Z; Wang Z; Chu X
    Cell Transplant; 2019 Dec; 28(1_suppl):76S-86S. PubMed ID: 31822116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioinformatics analyses of gene expression profile identify key genes and functional pathways involved in cutaneous lupus erythematosus.
    Gao ZY; Su LC; Wu QC; Sheng JE; Wang YL; Dai YF; Chen AP; He SS; Huang X; Yan GQ
    Clin Rheumatol; 2022 Feb; 41(2):437-452. PubMed ID: 34553293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Screening core genes and cyclin B2 as a potential diagnosis, treatment and prognostic biomarker of hepatocellular carcinoma based on bioinformatics analysis].
    Yang SY; Ren H; Li CF; Tang H
    Zhonghua Gan Zang Bing Za Zhi; 2020 Sep; 28(9):773-783. PubMed ID: 33053978
    [No Abstract]   [Full Text] [Related]  

  • 18. Construction of the miRNA-mRNA regulatory network and analysis of hub genes in oral squamous cell carcinoma.
    Cui Z; Song Q; Chen Y; Yang K
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Sep; 166(3):280-289. PubMed ID: 35132271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated bioinformatics analysis of potential biomarkers for pancreatic cancer.
    Shi H; Xu H; Chai C; Qin Z; Zhou W
    J Clin Lab Anal; 2022 May; 36(5):e24381. PubMed ID: 35403252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KEGG-expressed genes and pathways in triple negative breast cancer: Protocol for a systematic review and data mining.
    Chen J; Liu C; Cen J; Liang T; Xue J; Zeng H; Zhang Z; Xu G; Yu C; Lu Z; Wang Z; Jiang J; Zhan X; Zeng J
    Medicine (Baltimore); 2020 May; 99(18):e19986. PubMed ID: 32358373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.